fenofibrate All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

Cipher Reports Financial Results for Fiscal 2014
Cipher Pharmaceuticals (February 25, 2015)
New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
Merck & Co (February 25, 2015)
Ranbaxy Q3FY 2015 Sales Rs.25,876Mn. YTD Dec’14 Sales Rs.81,778Mn
Ranbaxy Laboratories (January 28, 2015)
VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Merck & Co (November 17, 2014)
Salix Pharmaceuticals Reports 3Q2014 Results
Salix Pharmaceuticals (November 06, 2014)
Ranbaxy Receives Approval From FDA To Market Fenofibrate Capsules USP, 43 mg And 130 mg
Ranbaxy Laboratories (November 05, 2014)
Cipher Reports Financial Results for Q3 2014
Cipher Pharmaceuticals (October 29, 2014)
FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain
Salix Pharmaceuticals (September 29, 2014)
Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN® 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea
Salix Pharmaceuticals (September 18, 2014)
Salix Secures Additional Intellectual Property Relating to Rifaximin
Salix Pharmaceuticals (September 18, 2014)

Displaying 10 out of a possible 511 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Summary Generic Name Information

Generic Name: fenofibrate
Therapeutic Subcategory:    Anti-hyperlipidaemics

Product Sales Summary

Annual Sales WW - Sales Growth per Year (%)
Rank1 Product Company 2010 2011 2011
Generic Name:2 fenofibrate 1,872 1,615 -14%
Note: Shaded Cells3

Evaluate - intelligence you can act on

Evaluate delivers market intelligence with standardized, transparent, integrated data that clients rely on.

Choose from a vast array of dynamic reports, customize, edit and download to PDF, Excel or create bespoke reports with expert client support.

Explore Content & Tools


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.  

Register Now